Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to -$44.7 million.

  • Wave Life Sciences' Cash from Operations rose 389.86% to -$44.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.4 million, marking a year-over-year decrease of 4035.64%. This contributed to the annual value of -$151.0 million for FY2024, which is 67724.26% down from last year.
  • Wave Life Sciences' Cash from Operations amounted to -$44.7 million in Q3 2025, which was up 389.86% from -$46.0 million recorded in Q2 2025.
  • Wave Life Sciences' 5-year Cash from Operations high stood at $85.5 million for Q1 2023, and its period low was -$63.0 million during Q1 2025.
  • Its 5-year average for Cash from Operations is -$28.5 million, with a median of -$33.4 million in 2022.
  • In the last 5 years, Wave Life Sciences' Cash from Operations crashed by 37547.28% in 2022 and then soared by 31448.6% in 2023.
  • Over the past 5 years, Wave Life Sciences' Cash from Operations (Quarter) stood at -$7.0 million in 2021, then crashed by 375.47% to -$33.4 million in 2022, then rose by 0.6% to -$33.2 million in 2023, then crashed by 31.32% to -$43.6 million in 2024, then dropped by 2.33% to -$44.7 million in 2025.
  • Its Cash from Operations stands at -$44.7 million for Q3 2025, versus -$46.0 million for Q2 2025 and -$63.0 million for Q1 2025.